Karyopharm to Participate at Jefferies Virtual Healthcare Conference
May 26, 2020 16:05 ET
|
Karyopharm Therapeutics Inc.
-- Fireside Chat Scheduled for Tuesday, June 2, 2020, at 9:30 a.m. ET -- NEWTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven...
Karyopharm Announces Investor Conference Call to Discuss Phase 3 BOSTON Data To Be Presented at the American Society of Clinical Oncology 2020 Virtual Scientific Program
May 26, 2020 07:00 ET
|
Karyopharm Therapeutics Inc.
-- Conference Call Scheduled for Friday, May 29, 2020 at 1:00 p.m. ET -- NEWTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven ...
Karyopharm Submits Supplemental New Drug Application to FDA for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy
May 20, 2020 08:00 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced it has submitted a supplemental New Drug...
Karyopharm Donates 60,000 Medical Masks Across Massachusetts and the United States in Partnership with Family Reach, Myeloma Crowd and The Leukemia & Lymphoma Society
May 13, 2020 08:00 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced a new initiative to donate and distribute...
Karyopharm to Participate at 2020 RBC Capital Markets Global Healthcare Virtual Conference
May 12, 2020 07:00 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
Karyopharm Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress
May 05, 2020 07:00 ET
|
Karyopharm Therapeutics Inc.
-- Pivotal Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival; Oral Presentation at ASCO 2020 Virtual Scientific Program and sNDA To Be Submitted by End...
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2020 16:05 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., May 01, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of...
Karyopharm Announces Data from Phase 3 BOSTON Study Selected for Late-Breaking Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program
April 29, 2020 13:58 ET
|
Karyopharm Therapeutics Inc.
- A Total of Five Abstracts Selected for Presentation, Including Two Highlighting Data from the Darzalex® and Kyprolis® Arms of the Phase 1b/2 STOMP Study - NEWTON, Mass., April 29, 2020 (GLOBE...
Karyopharm to Report First Quarter 2020 Financial Results on May 5, 2020
April 28, 2020 16:05 ET
|
Karyopharm Therapeutics Inc.
-- Conference Call Scheduled for Tuesday, May 5, 2020, at 8:30 a.m. ET -- NEWTON, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced that it will...
Karyopharm Announces Dosing of First Patient in Randomized Study Evaluating Low Dose Selinexor in Patients with Severe COVID-19
April 20, 2020 07:00 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., April 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced dosing of the first patient in a randomized Phase 2 clinical study evaluating low dose...